ACE2 and metabolic disease: Both SARS-CoV-1, which emerged in 2002, and the novel SARS-CoV-2 infect host cells through binding of their viral envelope spike (S) proteins to the same receptor, angiotensin-converting enzyme 2 (ACE2).3 Our group focused on the correlation between ACE2 and metabolic diseases since the outbreak of SARS-CoV-1 infection in 2003.